Skip to main content

Table 3 Comparison of the frequency of peripheral sensory neuropathy between present study and phase 3 trials

From: Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan

Regimen Grade Present study Phase 3 trials
CapeOX All Grade 54.4 % 78.0 %a
≥ Grade 3 1.80 % 11.0 %a
mFOLFOX6 All Grade 90.0 % 92.0 %b
≥ Grade 3 40.0 % 12.5 %b
  1. Grade of neuropathy was evaluated according to the Common Terminology Criteria for Adverse Events version 3.0.
  2. aData from reference [8]; bResult of FOLFOX4 [9]. Effectiveness and safety of mFOLFOX6 were comparable to those of FOLFOX4 [10].